Creating J&J's Cardiology Franchise: An Interview with Marv Woodall
Executive Summary
In this interview, Marv Woodall, the architect of Johnson & Johnson's cardiology business, reflects on the ups and downs of building a stent business, integrating a hostile takeover, and why--despite all their success--stents have not met their original goal.
You may also be interested in...
Prescient Medical's Dual Approach to Vulnerable Plaque
Vulnerable plaque caught investors' and entrepreneurs' attention several years ago as the mysterious cause of more than half of all cases of sudden cardiac death, most of which occurs in people with no history of heart disease. Several companies were launched and much money invested with little to show for it. One major problem: vulnerable plaque requires new tools both to diagnose and treat the condition, which proved to be bigger hurdles than most start-ups can overcome. Prescient was launched by an experienced device management team and is applying Raman spectroscopy, to coronary disease as the basis of its diagnostic tool, and is using a shield-not a stent-for its therapeutic device.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.